Theratechnologies, Inc. has terminated its distribution and licensing agreement with Ferrer International for the commercialization of tesamorelin in Europe, Russia, South Korea, Taiwan and certain Asian countries, for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. Ferrer was also responsible for regulatory activities for tesamorelin in these territories. Theratechnologies now holds all commercialization rights in these regions.
"We have been working diligently to forge the most appropriate path for tesamorelin in Europe following the withdrawal of the application last June. Our work in this regard continues and, at this juncture, Ferrer and Theratechnologies have mutually agreed to terminate their agreement," said Luc Tanguay, president and chief executive officer of Theratechnologies. “We are currently working with key physicians, patient groups, regulatory consultants and certain regulators to assess a potential re-filing in Europe for tesamorelin in 2013."
Currently, there are no approved treatments in Europe for lipodystrophy in HIV-infected patients.